Trial Profile

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary)
Indications Pulmonary arterial hypertension
Focus Therapeutic Use
Acronyms EXPEDITE
Sponsors United Therapeutics Corporation

22 May 2024 Results of this study presented at the 120th International Conference of the American Thoracic Society
28 Aug 2023 Results (n=29) assessing the effect of short course of parenteral treprostinil therapy in right-sided cardiac structural and functional parameters after a short course of parenteral treprostinil, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
24 May 2023 Results (n=29) presented at the 119th International Conference of the American Thoracic Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com